


PHARMACEUTICAL 2021



Checkpoint Therapeutics Inc. Rank 148 of 402





PHARMACEUTICAL 2021



Checkpoint Therapeutics Inc. Rank 148 of 402

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 152%, being 104% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	42,596
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,217
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	120
Other Revenues	1,069
Property and Equipment	0
Research and Development	16,352
Selling, General and Administrative Expense	7,918

Output Variable	Value in 1000 USD
Assets	42,596
Liabilities	7,217
Expenses	24,270
Revenues	1,069
Stockholders Equity	35,379
Net Income	-23,081
Comprehensive Net Income	-23,081
Economic Capital Ratio	152%

